A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

This study is testing a new injectable treatment called TQB2934 given under the skin for people with multiple myeloma (a cancer of plasma cells in the bone marrow) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple myeloma that has relapsed or is no longer responding to treatment - You have already tried at least one prior treatment including a proteasome inhibitor, an immunomodulator, and a CD38 antibody (such as daratumumab) - Your cancer has measurable signs of disease - You are in reasonably good general health **You may NOT be eligible if...** - You have received a bone marrow transplant from a donor within the past year, or your own stem cells within the past 3 months - You have received previous CD3×BCMA bispecific antibody therapy - You have active, uncontrolled infections, liver disease, or serious heart or lung conditions - You are pregnant, planning to become pregnant, or breastfeeding - You have had another cancer within the past 3 years Talk to your doctor to see if this trial is right for you.